Elicio Therapeutics (NASDAQ:ELTX) Bolsa

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Descubre las acciones que lideran el premercado con sorprendentes subidas y caídas. INNOVATE y más protagonistas hoy.

Las acciones de INNOVATE (VATE) cotizan un 19% más alto; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Elicio Therapeutics Inc

Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) reported quarterly losses of $(0.47) per share. This is a 14.63 percent decrease over losses of $(0.41) per share from the same period last year.

Earnings

PHIO

Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY

Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $(0.04) by 1625 percent. This is a 143.57 percent increase over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $5.50 million which beat the analyst consensus estimate of $4.30 million by 27.98 percent. This is a 47.96 percent decrease over sales of $10.57 million the same period last year.

Earnings Beats

AISP

Airship AI Holdings Q1 EPS $0.61 Beats $(0.04) Estimate, Sales $5.50M Beat $4.30M Estimate

General

SHOT

Safety Shot On May 9 Entered Securities Purchase Agreement For Purchase Of 641,000 Shares For Gross Proceeds Of $250,000

Seaport Global analyst Daniel Mckenzie maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Buy and lowers the price target from $103 to $89.

Price Target

Analyst Ratings

Seaport Global Maintains Buy on United Airlines Holdings, Lowers Price Target to $89

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 5 years by 11.39% on an annualized basis producing an average annual return of 26.51%. Currently, Live Nation Entertainment has a market capitalization of $34.11 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 5 years ago, it would be worth $315.10 today based on a price of $145.70 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747341913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Live Nation Entertainment 5 Years Ago Would Be Worth This Much Today

Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), which operates an online networking service for medical professionals, reported fiscal fourth-quarter financial results after the market close on Thursday. Shares appear to be moving lower due to weak guidance. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45450785/doximity-announces-fourth-quarter-and-fiscal-year-2025-financial-results">of the report</a>.
<ul class="wp-block-list">
<li>Q4 Revenue: $138.29 million, versus <a href="http://benzinga.com/quote/docs/earnings">estimates</a> of $133.73 million</li>
</ul>
<ul class="wp-block-list">
<li>Q4 Adjusted EPS: 31 cents, versus estimates of 27 cents</li>
</ul>
Total revenue climbed 17% year-over-year. Subscription revenue was also up 17%, totaling $131.9 million in the quarter. The company reported operating cash flow of $98.5 million and free cash flow of $97 million for the fourth quarter.
Doximity ended the quarter with approximately $209.61 million in cash and cash equivalents.
&#8220;We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,&#8221; said Jeff Tangney, co-founder and CEO of Doximity. &#8220;Our newsfeed, workflow and AI tools all hit fresh highs in the fourth quarter, helping doctors save time and provide the best care for their patients.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45453142/meta-platforms-stock-dips-on-ai-rollout-delay-amid-internal-turmoil-report">Meta Platforms Stock Dips On AI Rollout Delay Amid Internal Turmoil: Report</a>
Outlook: Doximity guided for fiscal first-quarter revenue of $139 million to $140 million versus estimates of $143.34 million, according to Benzinga Pro. The company also forecasted full-year 2026 revenue of $619 million to $631 million versus estimates of $634.6 million.
Doximity executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
DOCS Price Action: <a href="http://benzinga.com/quote/docs">Doximity shares</a> were down 24.48% in Thursday&#8217;s after-hours session, trading at $45.02 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Doximity.

Guidance

Health Care

DOCS

Doximity Stock Dives On Q4 Earnings As Guidance Comes In Below Estimates

Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimate of $(1.31) by 41.22 percent. This is a 97.11 percent increase over losses of $(64.08) per share from the same period last year. The company reported quarterly sales of $3.47 million which missed the analyst consensus estimate of $3.90 million by 10.93 percent. This is a 9.73 percent decrease over sales of $3.85 million the same period last year.

Earnings Misses

JTAI

Jet AI Q1 EPS $(1.85) Misses $(1.31) Estimate, Sales $3.47M Miss $3.90M Estimate

Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.04) by 575 percent. This is a 28.57 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $12.13 million which missed the analyst consensus estimate of $14.00 million by 13.32 percent. This is a 13.70 percent decrease over sales of $14.06 million the same period last year.

AIRI

Air Industries Q1 EPS $(0.27) Misses $(0.04) Estimate, Sales $12.13M Miss $14.00M Estimate

Falcons Beyond Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBYD#NASDAQ">FBYD</a>) reported quarterly losses of $(0.13) per share. This is a 110.2 percent decrease over earnings of $1.27 per share from the same period last year. The company reported $1.71 million in sales this quarter. This is a 12.66 percent increase over sales of $1.52 million the same period last year.

FBYD

Falcons Beyond Global Q1 EPS $(0.13) Down From $1.27 YoY, Sales $1.71M Up From $1.52M YoY

Signing Day Sports Q1 EPS $(0.44) Up From $(7.68) YoY, Sales $148.36K Down From $234.63K YoY

Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) reported quarterly losses of $(0.35) per share. This is a 75 percent increase over losses of $(1.40) per share from the same period last year. The company reported $238.49 thousand in sales this quarter. This is a 77.29 percent decrease over sales of $1.05 million the same period last year.

SIDU

Sidus Space Q1 EPS $(0.35) Up From $(1.40) YoY, Sales $238.49K Down From $1.05M YoY

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.16) per share. This is a 50 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.61 million which beat the analyst consensus estimate of $1.30 million by 23.62 percent. This is a 26.32 percent decrease over sales of $2.18 million the same period last year.

BKYI

BIO-key Intl Q1 EPS $(0.16) Up From $(0.32) YoY, Sales $1.61M Beat $1.30M Estimate

A trade war between China and the United States, involving President Donald Trump&#8217;s higher tariff prices, could be hurting the nation&#8217;s favorability rating. 
A new survey shows that net favorability for China has surpassed the United States for the first time since polling began in 2020.
What Happened: A new Morning Consult poll shows China ranking ahead of the U.S. for net favorability as of early April, <a href="https://www.benzinga.com/news/global/25/04/44620889/trumps-liberation-day-tariffs-roil-markets-as-china-slams-typical-unilateral-bullying-asian-markets-plunge">when </a><a href="https://www.benzinga.com/news/global/25/04/44620889/trumps-liberation-day-tariffs-roil-markets-as-china-slams-typical-unilateral-bullying-asian-markets-plunge" target="_blank" rel="noopener">Trump announced the </a>so-called Liberation Day, declaring tariff amounts on numerous countries worldwide. According to recent surveys, net favorability ratings have remained with China ahead for the month of April.
Morning Consult has <a href="https://pro.morningconsult.com/analysis/us-china-global-standing-competition">polled </a>residents in dozens of countries, 41 in the latest survey, over the years.
Countries included in the core data since 2020 include the United States, China, Australia, Brazil, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain and the United Kingdom. Ratings from a person's own country are removed from the rankings.
A <a href="https://x.com/cameron_easley/status/1922645080826847484" target="_blank" rel="noopener">chart </a>shows that the gap between China and the U.S. has increased since the 2024 election. This suggests that Trump&#8217;s win may have increased negative views of the U.S. by residents of other countries and/or China&#8217;s favorable ratings may have improved over the same period.
Trump's inauguration and quick tariff announcements worsened the United States&#8217; favorability rating.
At the start of 2025, 29 of the 41 core countries in the survey viewed the U.S. as more favorable than China. As of April 30, only 13 of the 41 countries favor the United States over China.
The net favorability rating for the United States appears to have improved after the recent 90-day reciprocal tariff pause between China and America, which will be closely monitored going forward to see if the U.S. can repass China.
Read Also:<a href="https://www.benzinga.com/trading-ideas/25/05/45144516/trump-a-grinch-or-santa-for-christmas-children-will-have-two-dolls-instead-of-30-dolls"> Trump A Grinch Or Santa For Christmas? &#8216;Children Will Have Two Dolls Instead Of 30 Dolls&#8217;</a>
 Why It's Important: Trump's approval rating has fallen in many polls in 2025, including a<a href="https://www.benzinga.com/25/05/45256510/exclusive-trumps-approval-rating-drops-in-reader-survey-after-100-days-could-stock-market-be-to-blame"> Benzinga reader poll</a> showing his approval rating at the 100-day mark lower than it was during his first 52 days in office.
One factor that could be hurting Trump's approval ratings and the country&#8217;s net favorability rating is the stock market returns, which have been impacted by tariffs.
The stock market indexes and stocks have fallen on tariff news, while items like the 90-day pause announcement have sent shares higher and put the S&amp;P 500 back in the green in 2025.
Trump's first 100 days in office saw the worst return for the S&amp;P 500 at the start of a four-year term since Richard Nixon in 1973. The S&amp;P 500 was down 7.8% in Trump's first 100 days, trailing the 9.9% drop in Nixon's first 100 days.
For comparison, the S&amp;P 500 has an average return of 2.1% in the first 100 days of a presidency, dating back to 1944.
While U.S. stocks have been hurt in 2025, Chinese stocks and ETFs have mostly outperformed.
Here's a look at the year-to-date returns of some of the top Chinese ETFs by assets under management:
<ul class="wp-block-list">
<li>KraneShares Trust China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>): +19.3%</li>
<li>iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>): +19.6%</li>
<li>iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>): +18.5%</li>
</ul>
Compare that to the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which are up 0.9% and 1.6%, respectively, on a year-to-date basis.
While stock market performance is only one factor, it would appear that the new presidency and tariffs are among the reasons other countries view the United States less favorably than China.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted">Trump&#8217;s First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted</a></li>
</ul>
Photo: Shutterstock

Politics

Global

KWEB

MCHI

China Tops US In Global Favorability After 'Liberation Day,'  Trump Tariffs Blamed For International Image Slide

Management

Sensata Technologies CFO Brian Roberts To Resign, Andrew Lynch Appointed Interim CFO Effective May 16

New Concept Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GBR#AMEX">GBR</a>) reported quarterly losses of $(0.01) per share. This is a 200 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $38.00 thousand in sales this quarter. This is a 5.56 percent increase over sales of $36.00 thousand the same period last year.

New Concept Energy Q1 EPS $(0.01) Down From $0.01 YoY, Sales $38.00K Up From $36.00K YoY

NVFY

Nova Lifestyle Q1 EPS $(0.03) Up From $(0.65) YoY, Sales $2.63M Up From $2.38M YoY

Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.23) by 39.13 percent. The company reported $6.324 million in sales this quarter. This is a 56.57 percent decrease over sales of $14.561 million the same period last year.

BEEM

Beam Glb Q1 2025 Adj. EPS $(0.32) Misses $(0.23) Estimate, Sales $6.324M Down From $14.561M YoY

CAVA Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45451578/cava-group-reports-first-quarter-2025-results">of the report</a>.
Q1 Earnings: Cava's first-quarter revenue increased 28.2% year-over-year to $331.83 million, beating the <a href="http://benzinga.com/quote/CAVA/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $326.88 million, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The Mediterranean fast-casual restaurant chain company reported first-quarter adjusted earnings of 22 cents per share, beating analyst estimates of 14 cents per share.
The company noted that net income included an income tax benefit of $10.7 million related to equity-based compensation.
Cava&nbsp;reported the same restaurant sales growth&nbsp;of 10.8% and traffic growth of 7.5%. The company said it opened 15 new restaurants during the quarter, bringing total locations up to 382, up 18.3% year-over-year.
Net cash provided by operating activities totaled $38.6 million and free cash flow came in at $2.7 million in the quarter. The company ended the period with $289.35 million in cash and cash equivalents.
&#8220;In spite of economic uncertainty and challenging weather, CAVA&#8217;s&nbsp;first quarter&nbsp;results demonstrate the continued strength of our category-defining brand,&#8221; said&nbsp;Brett Schulman, co-founder and CEO of Cava Group.
Guidance: Cava expects full-year same-restaurant sales growth to be between 6% and 8%, unchanged from prior guidance. The company expects to open between 64 and 68 new restaurants in total this year, up from prior guidance of 62 to 66 restaurants.
Cava&#8217;s management team will hold a conference call with investors and analysts to further discuss the quarter at 5 p.m. ET.
CAVA Price Action: <a href="https://www.benzinga.com/quote/CAVA" target="_blank" rel="noreferrer noopener">Cava shares</a> were down 4.10% in after-hours, trading at $95 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/news/25/05/45395034/heres-how-much-you-would-have-made-owning-chipotle-mexican-grill-stock-in-the-last-15-years">Here&#8217;s How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years</a></li>
</ul>
Photo: courtesy of Cava Group.

Restaurants

After-Hours Center

CAVA

Cava Group Reports Q1 Earnings: Revenue Jumps 28%, Company Bumps Up New Restaurant Openings Guidance

Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.23 million which missed the analyst consensus estimate of $2.43 million by 8.32 percent. This is a 0.76 percent decrease over sales of $2.25 million the same period last year.

MLSS

Milestone Scientific Q1 EPS $(0.02) Misses $(0.01) Estimate, Sales $2.23M Miss $2.43M Estimate

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)'s May 19 investor day arrives at a pivotal moment for the world's largest bank, with Wall Street watching closely for clarity on management succession and capital strategy as macroeconomic <a href="https://www.benzinga.com/news/econ-s">uncertainty clouds the outlook.</a>
Shares of JPMorgan have rebounded 33% since April's lows and now sit within 5% of February's all-time high, highlighting just how critical this event is for investors.
Up 12% year-to-date, JPMorgan has outpaced the broader Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), which gained just 5.4% in the same period. 
In a note Thursday, Bank of America's analyst Ebrahim Poonawala said the stock's premium is "well deserved but raises the bar for near-term outperformance." 
He called JPMorgan the best-positioned among peers to manage macro uncertainty and leverage opportunities in AI, digital assets, and private credit.
According to Poonawala, there are the five core themes traders and analysts will watch closely.
See Also: <a href="https://www.benzinga.com/25/04/45071155/mild-recession-is-best-case-outcome-jpmorgan-ceo-jamie-dimon">Jamie Dimon Says Recession Is Best-Case Scenario</a>
<h3 class="wp-block-heading">1. CEO Succession: Will Jamie Dimon Signal a Timeline?</h3>
The Street isn't ready for a post-Dimon JPMorgan. 
&#8220;Obviously, best&nbsp;case for investors could be another five years of CEO Jamie Dimon at the helm,&#8221; Poonawala said.
At 69, Jamie Dimon is younger than peers like BlackRock's Larry Fink (72) or Blackstone's Steve Schwarzman (78). 
Yet succession chatter is growing. Marianne Lake, CEO of the Consumer Bank, is seen as the <a href="https://fortune.com/2025/01/17/jennifer-piepszak-exited-jpmorgans-ceo-race-but-theres-still-one-woman-in-the-running-to-succeed-jamie-dimon/">frontrunner</a> after COO Jenn Piepszak reportedly stepped back.
Also in the mix is Troy Rohrbaugh, co-CEO of the Corporate and Investment Bank. Both have over two decades at JPMorgan, and the bank's leadership pipeline is widely viewed as deep and capable.
The company could follow either Morgan Stanley's timeline model or Berkshire Hathaway's pre-announcement style, but any news may cause short-term volatility before clarity brings back investor confidence.
<h3 class="wp-block-heading">2. Capital Deployment: Where Will The $62 Billion Go?</h3>
JPMorgan's balance sheet strength is unmatched. It holds $38 billion in capital above regulatory minimums, and with another $24 billion expected by year-end, the war chest could reach $62 billion—on par with the Fed's 2024 stress test losses.
Despite this, management is playing it safe. Buybacks, which have averaged $6 billion per quarter, remain the preferred use of capital. The bank continues to dismiss the idea of special dividends or big-ticket M&amp;A.
"Capital flexibility is a key asset for JPMorgan," said Poonawala, but he indicated that "management has downplayed any meaningful shift in capital deployment strategy," likely sticking with a near-100% capital return ratio through repurchases and dividends.
<h3 class="wp-block-heading">3. Revenue Outlook: A Net Interest Income Beat in Sight?</h3>
With fewer rate cuts now priced in—just two expected for 2025 versus three before—there's room for JPMorgan to raise its $90 billion net interest income forecast. Last year's guidance pegged NII in the mid-$70 billion range.
Capital markets remain a drag. Dealogic data shows JPM's investment banking fees down 24% year-over-year in second quarter, slightly better than the 29% drop for peers. Yet, fee-based businesses like wealth management and payments could cushion the blow.
Poonawala highlighted digital initiatives like Kinexys, JPM's blockchain-powered payments network, as potential long-term tailwinds, especially under a crypto-friendly White House.
<h3 class="wp-block-heading">4. Expense Discipline: Has Spending Peaked?</h3>
After four straight years of expense growth above 7%, JPMorgan may now guide toward a more sustainable 4%-6% range. 
Headcount growth is slowing, and tech spending as a share of revenue has declined for two consecutive years.
Importantly, despite elevated costs, the bank still leads peers in efficiency. Management signaled that cost savings would likely come from unit cost improvements, not outright budget cuts.
<h3 class="wp-block-heading">5. Credit Risk: Consumer Remains Resilient, For Now</h3>
With consumer credit in focus, JPMorgan&#8217;s card portfolio—17% of total loans—is once again under the microscope. The portfolio has grown 80% since 2015, far above the industry's 65%.
Still, quality remains high. About 86% of JPM card loans go to borrowers with FICO scores above 600, and delinquency rates are low at 2.1%.
Under a moderate stress scenario, management sees a potential 6% EPS hit in 2025. Worst-case losses, using Fed assumptions, could cut profits by half—but JPMorgan is better positioned than most to weather such an outcome.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Sector ETFs

Econ #s

ETFs

JPMorgan Investor Day Looms, Here Are 5 Core Topics To Watch

Press Releases

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Coherus BioSciences

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Immunic

Inozyme Pharma

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

OncoCyte

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Senti Biosciences

Instil Bio

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Jones Trading

Screenshot 2024-06-07 at 5.22.00 PM

Biotech

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Comments

Elicio Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL